World Bronchiectasis News Today

Electromed, Inc. (AMEX:ELMD) Q4 2023 Earnings Call Transcript August 22, 2023 Operator: Greetings, and welcome to Electromed’s Fourth Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] It is now my pleasure to introduce Mike Cavanaugh, Investor Relations. […]

/PRNewswire/ - Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies...

Inhaled colistimethate sodium showed a large benefit in one trial but produced almost no effect in the other, a result attributed to the COVID pandemic.

Two nonantibiotic strategies are moving forward as possible options for the most difficult NTM pathogens.

Patients with nontuberculous mycobacteria have more lung disease complications at baseline but their outcome at 5 years is almost same as that of patients with bronchiectasis alone.

According to data from the Bronchiectasis and NTM Registry, the presence of a positive fungal culture in bronchiectasis is not a predictor of more severe disease and has no major impact on outcome.

The meeting will focus on new research and debate the latest results and foster collaboration to accelerate progress in the treatment of treatment of bronchiectasis and NTM infections.

/PRNewswire/ -- Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by...